Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$105,000.00

Identification of XPO1 cargo and modulation by SINE compounds in diffuse large B cell lymphoma

EF 2023-24

Résumé
The structure of a human cell is divided into different compartments using barriers known as membranes. In these cells, the nucleus is separated from the cytoplasm by a nuclear membrane, which allows for the free passage of small molecules but requires more complex transport systems for molecules above a certain size limit. Exportin-1 (XPO1) is a nuclear export protein that shuttles both proteins and nucleic acids from the nucleus to the cytoplasm. Cancer cells have been shown to hijack XPO1 activity to mislocalize proteins that slow their growth or sensitize them to anti-cancer therapies, resulting in disease progression and treatment resistance. Selinexor is a new therapy that inhibits XPO1's nuclear export activity and has been found to be active in treating numerous cancer types. Since XPO1 can shuttle a large number of proteins, it is important to understand what protein cargo XPO1 is carrying in cancers where selinexor is used to treat patients. This is due to the fact that the types of protein cargo molecules may vary widely in different types of cancers, affecting how the drug works. This research project aims to uncover what XPO1 exports in a specific type of cancer called lymphoma. I will use a series of experiments to identify and validate XPO1 cargo molecules to better understand how XPO1 and selinexor work in lymphoma. Identifying the proteins and pathways affected by selinexor will allow for a better understanding of the drug's mechanism of anti-cancer activity in this disease. The mechanism by which selinexor affects cell growth, death, and other pathways relevant to cancer progression and drug resistance will also be studied. My data will be critical in helping identify other drugs that can be used with selinexor to formulate and test active combinations that will enhance our ability to kill lymphoma cells. We hope that these novel combinations can subsequently be tested in a clinical setting to improve the lives of patients living with lymphoma.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
496575
Name
Trkulja Kyla L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Identification of XPO1 cargo and modulation by SINE compounds in diffuse large B cell lymphoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Combination Therapies; Hematology; Lymphoma; Mass Spectrometry; Mechanism Of Action; Nuclear Export; Proteomics; Subcellular Fractionation
Abstract
The structure of a human cell is divided into different compartments using barriers known as membranes. In these cells, the nucleus is separated from the cytoplasm by a nuclear membrane, which allows for the free passage of small molecules but requires more complex transport systems for molecules above a certain size limit. Exportin-1 (XPO1) is a nuclear export protein that shuttles both proteins and nucleic acids from the nucleus to the cytoplasm. Cancer cells have been shown to hijack XPO1 activity to mislocalize proteins that slow their growth or sensitize them to anti-cancer therapies, resulting in disease progression and treatment resistance. Selinexor is a new therapy that inhibits XPO1's nuclear export activity and has been found to be active in treating numerous cancer types. Since XPO1 can shuttle a large number of proteins, it is important to understand what protein cargo XPO1 is carrying in cancers where selinexor is used to treat patients. This is due to the fact that the types of protein cargo molecules may vary widely in different types of cancers, affecting how the drug works. This research project aims to uncover what XPO1 exports in a specific type of cancer called lymphoma. I will use a series of experiments to identify and validate XPO1 cargo molecules to better understand how XPO1 and selinexor work in lymphoma. Identifying the proteins and pathways affected by selinexor will allow for a better understanding of the drug's mechanism of anti-cancer activity in this disease. The mechanism by which selinexor affects cell growth, death, and other pathways relevant to cancer progression and drug resistance will also be studied. My data will be critical in helping identify other drugs that can be used with selinexor to formulate and test active combinations that will enhance our ability to kill lymphoma cells. We hope that these novel combinations can subsequently be tested in a clinical setting to improve the lives of patients living with lymphoma.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Trkulja, Kyla L
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~